



ABN 53 075 582 740

## ASX ANNOUNCEMENT

16 September 2016

---

### **Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP**

Bionomics Limited (ASX: BNO, OTCQX:BNOEF), a clinical stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, will present two posters at the European College of Neuropsychopharmacology (ECNP) Congress in Vienna on Tuesday 20th September 2016.

One poster reports the results of the Phase 1b clinical trial completed in September 2015 in which BNC210 demonstrated target engagement. The other poster showcases an animal model of cognitive dysfunction which demonstrates the cognitive-enhancing efficacy of marketed drugs for attention deficit hyperactivity disorder (ADHD).

The first poster, *A multiple ascending dose study with evidence for target engagement of BNC210; a negative allosteric modulator of alpha7 nAChR in development for anxiety*, describes demonstration of target engagement by BNC210 as measured by quantitative electroencephalogram (qEEG).

BNC210 is a negative allosteric modulator of the of the alpha 7 nicotinic acetylcholine receptor (alpha7 nAChR) in development for the treatment of anxiety and stress-related disorders. Bionomics' research has demonstrated that single ascending doses of BNC210 are safe, well tolerated and avoid the side effects seen with standard of care drugs for anxiety such as benzodiazepines, Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Norepinephrine Reuptake Inhibitors (SNRIs).

This clinical trial investigated multiple ascending doses of BNC210 in healthy volunteers. Repeated administrations of BNC210 produced no detrimental effects on cognitive functions and was safe and well tolerated. A qEEG paradigm showed that BNC210 engaged with its target by inhibiting the effects of nicotine on the brain

BNC210 possesses significant potential in meeting a medical need for fast-acting anxiolytic agents that do not carry the side-effects of existing treatments such as sedation, addiction and negative effects on memory and coordination.

The second poster, co-authored with Bionomics' subsidiary, Neurofit SAS, presents data from an animal model of cognitive dysfunction that demonstrates the cognitive-enhancing efficacy of marketed drugs for ADHD; Strattera (Atomoxetine), Ritalin (methylphenidate) and Dexadrine (D-amphetamine). The model presents a novel method for assessing drugs in development for ADHD.

Copies of both posters will be available on Bionomics' website: [www.bionomics.com.au](http://www.bionomics.com.au) following presentation at ECNP.

Bionomics is currently evaluating BNC210 in Phase II trials for generalized anxiety disorder for which results are expected in Q3 2016, and post-traumatic stress disorder, which was initiated at the end of Q2 2016.

ECNP is an independent scientific association dedicated to the science and treatment of disorders of the brain. It is the largest non-institutional supporter of applied and translational neuroscience research and education in Europe.

**FOR FURTHER INFORMATION PLEASE CONTACT:**

**Australia**

Monsoon Communications  
Rudi Michelson  
+613 9620 3333  
[rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

**US**

Stern IR, Inc.  
Beth Del Giacco  
+1 212 362 1200  
[beth@sternir.com](mailto:beth@sternir.com)

**About Bionomics Limited**

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ( $\alpha 7$ ) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

[www.bionomics.com.au](http://www.bionomics.com.au)

**Factors Affecting Future Performance**

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.